RxDoctor Payments Data

Alissa Aylward

Physician Assistant · Cheyenne, WYNPI 1598241911

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.6% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Novartis at 33.9% of the total. Reporting peaked in 2022 at $503 and has fallen 52.4% since, to $239 in 2025.

$1,486in general payments, 2019–2025

Across 71 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$503
  • AbbVie$274
  • Regeneron Healthcare Solutions, Inc.$120
  • Amgen$113
  • Sun Pharmaceutical Industries Inc.$93
  • Sanofi-aventis U.S. LLC$80
  • plus $302 from 9 others

What the payments were for

  • Food & beverage$1,40695%
  • Education$805%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,486 in reported general payments places this provider in the 80th percentile of 203 physician assistant providers in Wyoming.

See all physician assistant providers in Wyoming

Medicare billing

Part B allowed, 2024
$286,079
Medicare patients
959
Services billed
4,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$88,550
OtezlaApremilast13$62,261
Clobetasol Propionate83$4,410
Fluorouracil59$4,264
Clindamycin Phosphate30$903
Doxycycline Hyclate29$495
Ketoconazole28$414
Triamcinolone Acetonide55$279
Mupirocin33$274
ValacyclovirValacyclovir Hcl12$237
Hydrocortisone28$190
Cephalexin12$82
Finasteride12$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$113$62,26113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 203 physician assistant providers in Wyoming.

Other physician assistant in Cheyenne

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →